Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer

Dan Yang¹, Yang He², Bo Wu³, Yan Deng¹, Nan Wang¹, Menglin Li¹ and Yang Liu¹*¹

Abstract

Background: Ovarian cancer (OC) ranks fifth as a cause of gynecological cancer-associated death globally. Until now, the molecular mechanisms underlying the tumorigenesis and prognosis of OC have not been fully understood. This study aims to identify hub genes and therapeutic drugs involved in OC.

Methods: Four gene expression profiles (GSE54388, GSE69428, GSE36668, and GSE40595) were downloaded from the Gene Expression Omnibus (GEO), and the differentially expressed genes (DEGs) in OC tissues and normal tissues with an adjusted P-value < 0.05 and a |log fold change (FC)| > 1.0 were first identified by GEO2R and FunRich software. Next, Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) analyses were performed for functional enrichment analysis of these DEGs. Then, the hub genes were identified by the cytoHubba plugin and the other bioinformatics approaches including protein-protein interaction (PPI) network analysis, module analysis, survival analysis, and miRNA-hub gene network construction was also performed. Finally, the GEPIA2 and DGIdb databases were utilized to verify the expression levels of hub genes and to select the candidate drugs for OC, respectively.

Results: A total of 171 DEGs were identified, including 114 upregulated and 57 downregulated DEGs. The results of the GO analysis indicated that the upregulated DEGs were mainly involved in cell division, nucleus, and protein binding, whereas the biological functions showing enrichment in the downregulated DEGs were mainly negative regulation of transcription from RNA polymerase II promoter, protein complex and apicolateral plasma membrane, and glycosaminoglycan binding. As for the KEGG-pathway, the upregulated DEGs were mainly associated with metabolic pathways, biosynthesis of antibiotics, biosynthesis of amino acids, cell cycle, and HTLV-I infection. Additionally, 10 hub genes (KIF4A, CDC20, CCNB2, TOP2A, RRM2, TYMS, KIF11, BIRC5, BUB1B, and FOXM1) were identified and survival analysis of these hub genes showed that OC patients with the high-expression of CCNB2, TYMS, KIF11, KIF4A, BIRC5, BUB1B, FOXM1, and CDC20 were statistically more likely to have poorer progression free survival. Meanwhile, the expression levels of the hub genes based on GEPIA2 were in accordance with those based on GEO. Finally, DGIdb database was used to identify 62 small molecules as the potentially targeted drugs for OC treatment.

Conclusions: In summary, the data may produce new insights regarding OC pathogenesis and treatment. Hub genes and candidate drugs may improve individualized diagnosis and therapy for OC in future.

Keywords: Ovarian cancer, Differentially expressed genes, Functional enrichment analysis, Protein-protein interaction, Survival analysis, miRNA-hub gene network
Introduction

Ovarian cancer (OC) ranks fifth as a cause of gynecological cancer-associated deaths globally [1], with an estimated 238,700 new cases and 151,900 deaths in 2012 [2]. There are many risk factors associated with OC, such as a family history of breast cancer or OC, excess body weight, smoking, earlier menstruation or later menopause, and not giving birth [2]. Due to the vague symptoms, more than 70% of OC cases are diagnosed at an advanced stage [3]. In most countries, the 5-year survival rate of OC is usually lower than 40% [4]. The poor prognosis and high mortality can be mainly attributed to the lack of early and effective detection methods [5]. Therefore, more efforts need to be invested towards the identification and understanding of novel biomarkers and specific targets of OC, which is considered the key to developing more effective diagnostic and therapeutic strategies.

Recently, gene profiles and gene chips have been used to screen differentially expressed genes (DEGs) [6]. Reanalyzing these data can provide new insights into current research on OC [7]. However, current studies on biomarkers may be insufficient, and the DEG results may be inconsistent because of the complex tumor heterogeneity and complicated molecular regulatory mechanism of OC. Furthermore, chemotherapy resistance remains a major challenge and causes most failures of treatment and the short overall survival (OS) and progression free survival (PFS) of OC patients. Many bioinformatical studies on OC have been proven to be effective and reliable [7, 8], which means integrated bioinformatics analysis could assist with exploring the biomarkers and the mechanisms underlying the tumorigenesis and progression of cancer.

In this study, four original gene expression profiles (GSE54388, GSE69428, GSE36668, and GSE40595) were downloaded from the Gene Expression Omnibus (GEO) database. DEGs were first screened based on the above four datasets. Subsequently, integrated bioinformatics analyses including Gene Ontology (GO) term analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, protein-protein interaction (PPI) construction, and the identification of hub genes were performed. Furthermore, survival analysis and validation of the hub genes were also performed. Finally, the miRNA-hub gene network was constructed, and targeted small molecular drugs for OC were identified.

Materials and methods

Data sources

The NCBI-GEO database is a free and public database containing gene profiles. Four microarray datasets (GSE54388, GSE69428, GSE36668, and GSE40595) were obtained from the GEO database (https://www.ncbi.nlm.nih.gov/gds/). The inclusion criteria for the above gene expression profiles were set as follows: (1) the tissue samples were obtained from human OC tissues and normal tissues; (2) the number of samples in each dataset was more than 8; (3) and all these profiles were based on GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array).

Identification of DEGs

GEO2R is an interactive web tool that can compare and analyze two different groups of samples under the same experimental conditions [9]. In this study, the selected datasets of OC tissues and normal tissues were first analyzed by GEO2R. Subsequently, the analyzed results were downloaded in Microsoft Excel format, and genes that met the cutoff criteria of the adjusted P-value < 0.05 and |log fold change (FC)| > 1.0 were considered DEGs [8]. Finally, the FunRich tool (version 3.1.3) was applied to illustrate the intersection of the DEGs. Additionally, an online tool, ClustVis, was used to draw the heatmap of the DEGs [10]. Specifically, the gene expression matrix for the heatmap was derived from GSE69428.

Functional enrichment analysis of DEGs

GO functional analysis and KEGG pathway analysis were carried out to predict the potential functions of the DEGs by using the Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/; version 6.8). Upregulated and downregulated DEGs were submitted to the DAVID online program. The top 10 items of the cellular component (CC), biological process (BP), and molecular function (MF) categories and KEGG pathways were then sorted and presented in the form of bubble maps. These bubble plots were drawn using the ggplot2 R package based on P-value through the statistical software R (version 3.6.1). P < 0.05 was considered statistically significant.

PPI network construction and module analysis

The PPI network of the identified DEGs was constructed by an online tool, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; https://string-db.org/), with an interaction score > 0.4. The active interaction sources included text mining, experiments, databases, coexpression, neighborhood, gene fusion, and corecurrence. Furthermore, the interaction network between the DEGs and their related genes was presented with the minimum number of interactions ≥ 2. Subsequently, the modules of the PPI network were screened by the Cytoscape software (version 3.7.1) plugin Molecular Complex Detection (MCODE) with default parameters as follows: degree cutoff = 2, node score cutoff = 0.2, k-score = 2, and max. Depth = 100. In this study, the criteria of the top four modules were set with MCODE scores ≥2.8 and nodes ≥3. KEGG pathway analysis of the genes in each module was performed by DAVID. Finally, based on the highest degree of connectivity, the top 10 genes were selected as the target hub genes by using the Cytoscape
Results

Identification of DEGs in OC

Four expression profiles (GSE54388, GSE69428, GSE36668, and GSE40595) were obtained from the GEO database. The specific details of the above datasets are presented in Table 1. In this study, the microarray datasets were all based on the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array). Three of the datasets were from SOC, and GSE40595 was from OC stroma (Table 1). GSE54388 consisted of 16 cases and 6 controls; GSE69428 contained 10 cases and 10 controls; GSE36668 included 4 cases and 4 controls; and GSE40595 contained 63 cases and 14 controls (Table 1). The Venn diagrams indicated that a total of 171 DEGs were identified from the four microarray profile datasets, including 114 upregulated genes and 57 downregulated genes in OC tissues compared to normal controls (Fig. 1 and Table 2). In addition, the expression levels of these DEGs were visualized in the form of a heatmap in Additional file 1: Figure S1.

Functional enrichment analysis of DEGs

A total of 114 upregulated genes and 57 downregulated genes were analyzed by DAVID software. The top 5 significant terms from the GO enrichment analysis showed that in the BP category, the upregulated DEGs were involved in cell division, mitotic nuclear division,
regulation of the cell cycle, DNA replication, and cellular response to DNA damage stimulus (Fig. 2a), whereas the downregulated DEGs were significantly involved in the negative regulation of transcription from the RNA polymerase II promoter, the positive regulation of transcription from the RNA polymerase II promoter, skeletal muscle tissue development, the viral process, and the regulation of phosphatidylinositol 3-kinase signaling (Additional file 2: Table S1). For the CC category, the upregulated DEGs were correlated with the nucleus, cytoplasm, cytosol, nucleoplasm, and extracellular exosomes (Fig. 2b), whereas the downregulated DEGs were associated with the protein complex and apicolateral plasma membrane (Additional file 2: Table S1). For the MF category, the upregulated DEGs were enriched in protein binding, identical protein binding, protein homodimerization activity, enzyme binding, and protein heterodimerization activity (Fig. 2c), whereas the downregulated DEGs were related to glycosaminoglycan binding (Additional file 2: Table S1). For KEGG pathway enrichment analysis, the downregulated DEGs were not enriched, whereas the top five significant KEGG pathways of the upregulated DEGs included metabolic pathways, biosynthesis of antibiotics, biosynthesis of amino acids, the cell cycle, and human T-lymphotropic virus type I (HTLV-I) infection (Fig. 2d). Furthermore, specific information on the upregulated DEGs identified in each category in the functional enrichment analysis are presented in Additional file 3: Table S2.

PPI network construction and module analysis

The PPI network of the DEGs in OC was constructed based on the information obtained from the STRING database. When 171 DEGs were submitted to the STRING database, there were 3 unidentified gene IDs, namely, WHAMMP2, WHAMMP3, and FAM153C. Subsequently, 168 genes were mapped into the PPI network. The PPI network included 168 nodes and 450 edges, and its PPI enrichment $P$-value was lower than $1.0 \times 10^{-16}$ (Additional file 4: Figure S2). In addition, an interaction network of 168 DEGs and their neighboring genes was constructed through FunRich (Additional file 5: Figure S2).

### Table 2: Information on the overlapping DEGs screened from the datasets

| DEGs | Gene name |
|------|-----------|
| Upregulated (114) | WHSC1, VEGFA, TYMS, TSTA3, TPI1, TPSD2L2, TOP2A, TNNT1, TMPRSS4, TIMELESS, C20orf24, TBC1D7, TACC3, STC2, SORT1, BOLA2, SLC5A2A, SLC4A11, SLC39A4, SLC38A1, SLC2A1, SHMT2, SCRIB, SAC1D1, S100A2, RRM2, RNASDH2A2, RACGAP1, PXDN, PLN1, PTTG1, P5AT1, PPP1R11B, PIGR3, PKB, OVL2, NR2F6, NOV, NDUF9, NDC80, NAPG, NCAPG, MCL1, MUC15, MT1F, MRPS11, MRPL12, MLF2, MCM4, MCM6, MAL, LSM4, LPCAT1, C1orf186, LAPTMB4, KL8, KL7, KL6, KL5, KIF1A, KIF11, KIAA0101, ISG15, IRAK1, IDH2, H1, HMG3B, HMGAI, H2AFX, GRPSM2, FOXN1, GTF18, FUS1, FDR, ESRP1, EFT1, ELO1, EOE2, ERF2, DTL, DSC2, DPP3, DHC2R4, DGAT1, DDX39A, DBN1, CYC1, CTPS1, CRABP2, COPE, COL4A1, CLTMT1, CLDN3, CHD7, C6H6, CDC4, CDC20, CD47, CCNE1, CCR2, C1orf16, C1orf106, BUB1B, BOLA2B, BIRC5, BAK1, AURKAIP1, ATP6V1B1, AS51, ARL4C, ARF3, APOAI, AIF1, ABDH11 |
| Downregulated (57) | ZEB2, ZBTB20, WHAMMP2, WHAMMP3, WDR17, TLE4, THBD, TPI1, SYTL3, SNCAP, SIMM14, SLC4A4, SDC5, RUNX1T1, RUNCDC3B, RNASE4, PTPN13, PRKAR1A, PCL2, PIP5K1B, PDCK4, PDGFRA, NDNF, NBEA, NABP2L2, NABP2L1, MPDZ, MITF, MEF2C, MAF, FAM153A, FAM153B, FAM153C, KLHC1D1, KL2, KAT2B, KANSIL1, ITM2A, IL6ST, GPRAS1, GNG11, FOXP2, DPyd, DPY19L2P2, DMD, DCM, CXorf57, CIRBP, CHGB, CELF2, CDC14A, BNC2, ARMCC1, ALDH1A1, ABCA8, ABCAS, AASS |

A total of 171 DEGs were identified from the four gene expression profiles, including 114 upregulated DEGs and 57 downregulated DEGs in OC tissues compared to normal tissues.
Figure S3). Then, the significant modules were identified via the MCODE plugin. As illustrated in Additional file 6: Figure S4, the top four functional clusters of modules were selected (module 1, MCODE score = 21.826; module 2, MCODE score = 3.333; module 3, MCODE score = 3; and module 4, MCODE score = 2.8). KEGG pathway analysis of each module was performed by DAVID, as shown in Additional file 6: Figure S4A. The KEGG pathway analysis of module 1 indicated that these genes were involved in the cell cycle, DNA replication, and oocyte meiosis (Additional file 7: Table S3). Module 2 consisted of 4 nodes and 5 edges (Additional file 6: Figure S4B), with genes enriched in ribosomes (Additional file 7: Table S3). Module 3 contained 3 nodes and 3 edges (Additional file 7: Table S3).
file 6: Figure S4C), with genes related to the biosynthesis of amino acids, the HIF-1 signaling pathway, and carbon metabolism (Additional file 7: Table S3). Finally, module 4 comprised 6 nodes and 7 edges (Additional file 6: Figure S4D), with genes associated with fat digestion and absorption and the PPAR signaling pathway (Additional file 7: Table S3). The PPI enrichment P-value of each module was lower than 0.05.

Ten genes (TYMS, CCNB2, KIF11, RRM2, CDC20, TOP2A, BUB1B, BIRC5, KIF4A, and FOXM1) with the highest degree scores were identified as the hub genes for OC by applying the cytoHubba plugin (Additional file 8: Table S4). All the hub genes were upregulated DEGs, as shown in Table 2. Additionally, the STRING online database was used to construct the PPI network of the hub genes (Fig. 3a), and FunRich software was used to draw the interaction network of the hub genes and their related genes (Fig. 3b). As shown in Fig. 3a, the PPI network of the hub genes consisted of 10 nodes and 45 edges, while its average local clustering coefficient was 1, and its PPI enrichment P-value was lower than 1.0e-05.

Survival analysis, genetic information and hub gene expression

The prognostic information of these 10 hub genes for OC and SOC at different stages was analyzed by the Kaplan-Meier plotter database. A survival prognosis forest map of these genes in early stage (Stages 1 and 2) is shown in Fig. 4a, and the survival curves of these genes are presented in Fig. 4b-k. Among the 10 hub genes, 8 hub genes were significantly associated with the PFS of OC patients at an early stage (stages 1 and 2) (Fig. 4). Except for TOP2A [HR = 1.19 (0.67–2.09), P = 0.55] (Fig. 4) and RRM2 [HR = 1.22 (0.69–2.15), P = 0.50] (Fig. 4), early-stage OC patients with higher expression levels of CCNB2 [HR = 1.87 (1.04–3.37), P = 0.033] (Fig. 4d), TYMS [HR = 2.04 (1.14–3.67), P = 0.014] (Fig. 4k), KIF11 [HR = 2.73 (1.48–5.03), P < 0.001] (Fig. 4h), KIF4A [HR = 2.82 (1.51–5.27), P < 0.001] (Fig. 4g), BIRC5 [HR = 2.85 (1.53–5.31), P < 0.001] (Fig. 4b), BUB1B [HR = 2.86 (1.55–5.29), P < 0.001] (Fig. 4c), FOXM1 [HR = 3.03 (1.60–5.73), P < 0.001] (Fig. 4f), and CDC20 [HR = 3.87 (2.01–7.46), P < 0.001] (Fig. 4e) were significantly related to poorer PFS (Fig. 4).

For SOC patients at stages 1 and 2, except for RRM2, FOXM1, and TOP2A, the remaining 7 hub genes presented statistically significant trends (Additional file 9: Figure S5). In addition, the relationship between PFS and the expression of these 10 hub genes in OC and SOC patients in “all stages” and “advanced stages” are presented in Additional file 10: Figures S6, Additional file 11: Figure S7, Additional file 12: Figure S8, and Additional file 13: Figure S9. More interestingly, increased expression of KIF4A and TYMS were related to poorer PFS in early stage (stages 1 and 2) OC and SOC patients (Fig. 4g, k, Additional file 9: Figure S5G & K), whereas decreased expression of the above 2 hub genes were associated with better PFS in advanced stage (stages 3 and 4) OC and SOC patients (Additional file 12: Figure S8 and Additional file 13: Figure S9). Subsequently, cBioPortal was used to determine the genetic alteration information of the 10 hub genes, as illustrated in Fig. 5. The network shown in Fig. 5a consists of 60 nodes, including 10 hub genes and the 50 most frequently altered neighboring genes (out of a total of 767). Drugs targeting the 10 hub genes are also presented in Fig. 5a. From this network, only KIF11, TOP2A, RRM2, TYMS, and BIRC5 are currently considered chemotherapy targets (Fig. 5a). Alteration information of the 10 hub genes is shown in Fig. 5b and c. As presented in Fig. 5b, the hub genes were altered in 173 (30%) queried patients or samples. CDC20 and FOXM1 were altered most often (7 and 7%, respectively). These alterations included amplification, deep deletion, truncating mutation, missense mutation, inframe mutation, and fusion (Fig. 5b). Among the different types of alterations, amplification accounted for the highest percentage (Fig. 5c).

Additionally, the GEPIA2 database was used to verify the expression levels of the 10 hub genes in tumor and normal tissues. As shown in Fig. 6a-j, the expression levels of the 10 hub genes were all statistically significant (P < 0.01) in OC and normal tissues on the basis of gene expression profiles from The Cancer Genome Atlas (TCGA) and the genotype-tissue expression (GTEx) projects. The results of the expression trends in OC patients and healthy people based on the GEPIA2 database were in accordance with those based on the GEO datasets (Fig. 6a-j and Table 2). Thus, both the GEPIA2 and GEO databases indicated that the mRNA expression levels of the 10 hub genes were upregulated in tumor tissues (Fig. 6a-j and Table 2). Additionally, the expression levels of the 10 hub genes in different stage OC patients are shown in Fig. 7. According to these results, it is easy to see that there were significant variations in the expression levels of BUB1B [Pr (>F) < 0.001] (Fig. 7b), FOXM1 [Pr (>F) = 0.007] (Fig. 7e), KIF4A [Pr (>F) = 0.022] (Fig. 7f), RRM2 [Pr (>F) = 0.025] (Fig. 7h), and TYMS [Pr (>F) = 0.002] (Fig. 7j) in OC patients in different stages. The overall trends indicated that the expression of the above five genes decreased gradually with the continuous progression of OC (Fig. 7).

miRNA-hub gene network

ENCORI was applied to screen the targeted miRNAs of the hub genes. The miRNAs predicted by at least two databases (among the following databases: miRanda, PITA, PicTar, and TargetScan) were identified as the targeted
Fig. 3 PPI network and coexpression analysis of the hub genes in OC. a The PPI network of the hub genes using the STRING online database. b The interaction network of the hub genes and their related neighboring genes using the FunRich software. c The coexpression analysis of the hub genes using the STRING online database.
miRNAs of the hub genes. Then, Cytoscape software was used to draw the miRNA-hub gene network. As illustrated in Fig. 8, the interaction network consists of 9 hub genes and 116 miRNAs. Moreover, the contribution level of the miRNAs to their surrounding hub genes is presented as the number of arrows (Fig. 8). According to the top 10 molecules in the network ranked by their degree of connectivity using cytoHubba, KIF11 (degree score = 47), RRM2 (degree score = 38), TOP2A (degree score = 23), and FOXM1 (degree score = 20) were clearly the four interactive hub genes that most miRNAs would target (Fig. 8), followed by BIRC5 (degree score = 14), KIF4A (degree score = 11), BUB1B (degree score = 6), and TYMS (degree score = 5). Furthermore, hsa-miR-377-3p (degree score = 4) and hsa-miR-335-5p (degree score = 4) were the top two interactive miRNAs that

---

**Fig. 4** Progression free survival analyses of hub genes in patients with stage 1 or 2 OC. 

- **a** Survival prognosis forest map of the hub genes related to prognosis in OC patients. Each point in the forest plot represents the hazard ratio (HR) of the gene, and the line on both sides of the point represents the 95% confidence interval (95% CI).
- **b-k** Survival curves were constructed by the Kaplan-Meier plotter online database based on the low and high expression of the hub genes in OC patients. Log-rank $P < 0.05$ was considered statistically significant.
targeted the most target hub genes (Fig. 8). Additionally, the respective miRNAs targeting the 10 hub genes are presented in Additional file 14: Table S5.

Drug-gene interaction
A total of 62 potential drugs for treating OC patients were identified when the drug-gene interactions were explored using DGIdb (Table 3). In this study, according to the statistically significant results of the survival analysis, TYMS and BIRC5 were selected as the potential targets of 62 drugs (Table 3). Both hub genes have been verified as current chemotherapy targets based on cBioPortal (Fig. 5a). As demonstrated in Table 3, the promising 62 candidate drugs were all approved by the FDA. Most potential drugs

![Fig. 5](image_url)

Information on the genetic alterations of the hub genes. a The association between the hub genes and related drugs was identified by cBioPortal, and the network of 10 hub genes and the 50 most frequently altered neighboring genes was also constructed. b The genetic alterations related to the hub genes are shown through a visual summary across a set of ovarian serous cystadenocarcinoma samples (data from TCGA, PanCancer Atlas). c An overview of the alterations of the 10 hub genes in the genomics datasets of ovarian serous cystadenocarcinoma in the TCGA database

![Fig. 6](image_url)

The expression level of hub genes in OC tissues and normal tissues from patients (a-j). To further verify the expression level of the hub genes between OC tissues and normal tissues, the hub genes were analyzed by the GEPIA2 online database. *P < 0.01 was considered statistically significant.
might interact with the TYMS (32/62), either in some unknown manners or as an inhibitor (Table 3). The down-stream interaction networks of TYMS and BIRC5 were constructed by STITCH (Additional file 15: Figure S10). As shown in Additional file 15: Figure S10, TYMS might have downstream effects on 5-thymidylate (poly(dT)), 5-fluorouracil, deoxyuridine monophosphate (FdUMP), pemetrexed, methotrexate, OSI-7904 L, raltitrexed, dihydrofolate, and dihydrofolate reductase (DHFR) (Additional file15: Figure S10A), whereas BIRC5 might have downstream effects on exportin 1 (XPO1), poly-like kinase 1 (PLK1), cyclin-dependent kinase 1 (CDK1), cell division cycle associated 8 (CDCA8), aurora kinase A (AURKA), aurora kinase (AURKB), inner centromere protein antigens (INCENP), baculoviral IAP repeat-containing 2 (BIRC2), caspase 9 (CASP-9), and IAP-binding mitochondrial protein (DIABLO) (Additional file 15: Figure S10B).

Discussion

Although great progress on surgical and medical therapy has been made for OC, the overall mortality of OC remains the fifth cause of death among malignant gynecologic tumors. The causes of death from OC are mainly attributed to a lack of detection methods at an early stage, a high tendency for metastasis, and chemotherapy resistance [12, 13]. Therefore, exploring reliable biomarkers and precise molecular mechanisms for the early diagnosis, treatment, and prognosis of OC is urgent and necessary. In recent years, with the rapid development of bioinformatics, an increasing amount of microarray and sequencing data have provided a convenient and comprehensive platform to explore general genetic alterations, identify DEGs, and elucidate molecular mechanisms for the diagnosis, therapy, and prognosis of tumors [14].

In this study, four GEO datasets, namely, GSE54388, GSE69428, GSE36668, and GSE40595, were selected to screen DEGs. Applying the GEO2R tool and FunRich software, the intersection of 171 DEGs was identified, including 114 upregulated DEGs and 57 downregulated DEGs. Then, GO and KEGG pathway analyses of the DEGs were performed by DAVID. The KEGG pathway results showed that the upregulated DEGs were mainly associated with metabolic pathways, the biosynthesis of antibiotics, the biosynthesis of amino acids, the cell cycle, and HTLV-I infection, whereas the downregulated DEGs were not enriched. These results also provide significant clues to studying molecular interactions in the progression of OC.

Fig. 7 The expression level of hub genes in OC tissues at different stages (a-j). To further verify the expression level of the hub genes in OC tissues at different stages, the hub genes were analyzed by the GEPIA2 online database. ANOVA was performed to assess the statistical significance of the variations. Pr (>F) < 0.05 was considered statistically significant.
could be effective in treating OC [18–21]. Furthermore, Plewa S et al. once quantitated 42 serum-free amino acids and distinguished amino acid metabolic pathways related to OC growth and development [22]. However, the association between HTLV-I and OC remains unclear. In this study, the upregulated DEGs were mainly involved in biological functions such as cell division, the nucleus, and protein binding. The downregulated DEGs were mainly enriched in biological functions such as the negative regulation of transcription from the RNA polymerase II promoter, the protein complex, the apicolateral plasma membrane, and glycosaminoglycan binding.

Furthermore, a PPI network with 168 nodes and 450 edges was constructed based on the DEGs, and 10 hub genes with the highest degrees of connectivity in the PPI network were identified. Subsequently, survival analysis of these hub genes demonstrated that 8 upregulated hub genes (CCNB2, TYMS, KIF11, KIF4A, BIRC5, BUB1B, FOXM1, and CDC20) were significantly associated with a poorer PFS in OC patients at an early stage (stages 1 and 2). Then, the GEPIA2 database was used to further verify the expression levels of these hub genes in tumor and normal tissues, and the results were in accordance with those from the GEO database. The expression
| No. | Gene   | Drug                   | Interaction types | Sources                        | PMIDs                                      |
|-----|--------|------------------------|-------------------|-------------------------------|--------------------------------------------|
| 1   | TYMS   | ETOPOSIDE             | –                 | PharmGKB                       | –                                          |
| 2   | TYMS   | IRINOTECAN            | –                 | CIViC                         | 20,628,391                                 |
| 3   | TYMS   | VINCristine           | –                 | NCI                           | 2,804,079                                  |
| 4   | TYMS   | FOLIC ACID            | –                 | PharmGKB                       | –                                          |
| 5   | TYMS   | TOPOTECAN             | –                 | NCI                           | 10,803,925                                 |
| 6   | TYMS   | CYTARABINE            | –                 | PharmGKB                       | –                                          |
| 7   | TYMS   | MITOMYcin             | –                 | NCI                           | 15,218,314                                 |
| 8   | TYMS   | PREDnisone            | –                 | PharmGKB                       | –                                          |
| 9   | TYMS   | TRIFLURIDINE inhibitor | DrugBank           |                               | 18,600,528; 16,902,987; 20,372,850; 19,816,940; 19,886,911; 4,719,131; 6,436,227; 15,571,283; 17,179,993; 14,719,072; 16,010,590; 15,125,867; 11,752,352; 18,798,063; 6,010,427 |
| 10  | TYMS   | DAUNORUBICIN          | –                 | NCI                           | 2,967,076                                  |
| 11  | TYMS   | HYDROCORTISONE        | –                 | NCI                           | 2,707,640                                  |
| 12  | TYMS   | PRALATREXATE inhibitor | DrugBank           |                               | 23,409,799                                 |
| 13  | TYMS   | PHENTOLAMINE          | –                 | NCI                           | 2,866,100                                  |
| 14  | TYMS   | TRIMETHOPRIM inhibitor | DrugBank           |                               | 8,538,681; 10,090,784; 10,592,235; 17,139,284; 8,920,005; 17,016,423; 19,622,858 |
| 15  | TYMS   | INDOMETHACIN          | –                 | NCI                           | 2,707,640                                  |
| 16  | TYMS   | GEMCITABINE inhibitor | DrugBank           |                               | 16,563,096; 15,795,320; 17,166,391; 16,818,276; 11,752,352; 15,655,042; 16,818,496 |
| 17  | TYMS   | ASPARAGINASE          | –                 | PharmGKB                       | –                                          |
| 18  | TYMS   | CAPECITABINE inhibitor | ClearityFoundationClinicalTrial; ClearityFoundationClinicalTrial; GuideToPharmacologyInteractions; ChemblInteractions; DrugBank | 15,134,221; 16,926,630; 15,866,500; 15,132,128; 11,752,352; 15,709,193 |
| 19  | TYMS   | FLOXURIDINE inhibitor | TdgClinicalTrial; ClearityFoundationClinicalTrial; ChemblInteractions; TEND; DrugBank | 10,697,523; 10,891,536; 10,697,524; 10,482,907; 10,553,409 |
| 20  | TYMS   | LEUCOVORIN            | –                 | TdgClinicalTrial; TEND         | –                                          |
| 21  | TYMS   | TAMOXIFEN             | –                 | NCI                           | 9,615,734                                  |
| 22  | TYMS   | VERAPAMIL             | –                 | NCI                           | 3,436,366                                  |
| 23  | TYMS   | RALTITREXED inhibitor | PharmGKB; TdgClinicalTrial; GuideToPharmacologyInteractions; TEND; DrugBank | 18,773,878; 10,598,555; 10,430,100; 10,592,235; 11,752,352; 10,499,608; 10,482,907; 10,474,461; 10,496,350 |
| 24  | TYMS   | PEMETREXED DISODIUM   | inhibitor         | ChemblInteractions             | –                                          |
| 25  | TYMS   | DEXAMETHASONE         | –                 | NCI                           | 2,707,640; 3,398,844                        |
| 26  | TYMS   | INTERFERON GAMA-1B    | –                 | NCI                           | 1,557,656                                  |
| 27  | TYMS   | FLUOROURACIL inhibitor | ClearityFoundationClinicalTrial; ChemblInteractions; CIViC; DrugBank | 16,563,096; 20,628,391; 16,609,021; 16,719,540; 16,596,248; 16,538,493; 11,752,352; 15,353,299 |
| 28  | TYMS   | OXALIPLATIN           | –                 | PharmGKB                       | –                                          |
| 29  | TYMS   | TEGAFUR               | –                 | TdgClinicalTrial              | –                                          |
| 30  | TYMS   | SULFASALAZINE         | –                 | PharmGKB                       | –                                          |
| 31  | TYMS   | PEMETREXED (CHEMBL1201258) inhibitor | ClearityFoundationBiomarkers; TdgClinicalTrial; GuideToPharmacologyInteractions; CIViC; TEND | 23,645,741; 23,060,591; 21,367,480; 26,502,926 |
| 32  | TYMS   | METHOTREXATE          | –                 | CIViC                         | 23,652,803                                 |
| 33  | BIRC3  | IRINOTECAN            | –                 | NCI                           | 15,956,246                                 |
| 34  | BIRC3  | INTERFERON BETA-1A    | –                 | NCI                           | 12,117,359                                 |
levels of hub genes in different stage OC patients were also conducted. Considering the significant variations in the expression levels of KIF4A and TYMS in early and advanced stage OC patients (Fig. 7), we hypothesized that this result may explain why KIF4A and TYMS were related to poorer PFS in early stage (stages 1 and 2) OC and SOC patients (Fig. 4g, k, Additional file 9: Figure S5G, & K), whereas the 2 hub genes described above were associated with better PFS in advanced stage (stages 3 and 4) OC and SOC patients (Additional file 12: Figure S8 and Additional file 13: Figure S9). Thus, we further hypothesized whether KIF4A and TYMS might be considered as the tumor marker in the diagnosis of early OC. It is well known that tumor invasion and metastasis are always accompanied by complicated molecular regulatory mechanisms. In this study, the expression levels of all hub genes were dysregulated in OC tissues compared with normal tissues, meaning that these genes may be crucial to tumorigenesis and progression in OC. Although many studies have studied these hub genes connected with the diagnosis, treatment, and prognosis of various carcinomas, the molecular mechanisms underlying the tumorigenesis and progression of OC have not been fully understood.

First, kinesin family member 4A (KIF4A) is a microtubule-based motor protein that has been reported to be associated with various cancers, such as oral squamous cell carcinoma, cervical cancer, breast cancer, prostate cancer, colorectal cancer, and lung cancer [23–28]. However, there have been no studies conducted on KIF4A in regard to OC. In this study, the downregulated expression of KIF4A was correlated with poorer PFS in OC patients, especially in SOC patients at an
early stage (Fig. 4g, Additional file 6: Figure S4G). We also found 11 potential miRNAs (hsa-miR-183-5p, hsa-miR-223-3p, hsa-miR-136-5p, hsa-miR-150-5p, hsa-miR-376c-3p, hsa-miR-375, hsa-miR-335-5p, hsa-miR-494-3p, hsa-miR-411-5p, hsa-miR-421, and hsa-miR-543) that KIF4A might target (Fig. 8).

The overexpression of many cyclins has been reported in many tumors [29]; cyclin B2 (CCNB2) is located on the Golgi apparatus during the whole cell cycle and may cause a compromised G2/M transition in Hec1-depleted mouse oocytes [30, 31]. However, the association between CCNB2 and OC is not clearly understood. Cell division cycle 20 (CDC20) is an activator of the ligase anaphase-promoting complex/C (APC/C) that has been identified as a key candidate gene in OC patients based on many bioinformatics studies [32, 33]. High expression levels of CDC20 have been reported to be correlated with poor prognosis in a variety of cancers [34–36]. However, its specific molecular mechanisms underlying OC have not been fully explained. In this study, the survival analysis of CDC20 in OC patients at an early stage suggested that higher CDC20 expression could be related to poorer prognosis (Fig. 4e).

Thymidylate synthase (TYMS) is crucial for DNA synthesis in both normal and tumor cells. Biasin P et al. calculated six TYMS polymorphisms related to OS in epithelial OC (EOC) through a multivariate analysis and found that the TYMS 1494ins/del, 1053C > T and IVS6-68C > T polymorphisms might be considered prognostic markers for OS in EOC patients [37]. Additionally, Kelemen LE et al. also reported that re495139 in the TYMS-ENOSF1 region was associated with the risk of OC by evaluating large samples of assembled cases [38, 39]. KIF11, a member of the kinesin-like protein family, was once identified as a hub gene in OC by Zhanzhan Xu et al. [8], and they also found that KIF11 was potentially targeted by hsa-miR-424 and hsa-miR-381. A recent study explored whether death receptor 6 can promote OC cell migration by interacting with KIF11 and TNF receptor-associated factor 4 [40]. In this study, KIF11 was also considered a chemotherapy target for OC using cBioPortal (Fig. 5a).

Ribonucleotide reductase M2 (RRM2) is the regulatory subunit of ribonucleotide reductase and is not only involved in the tumorigenesis and progression of a variety of carcinomas (such as colon, breast, and pancreatic cancer) [41–43] but also leads to resistance to cancer chemotherapy [44]. Katherine M Aird et al. found that the knockdown of RRM2 expression could inhibit the growth of human EOC cells by triggering cellular senescence [45], which suggests that RRM2 might be a novel prosenescence therapeutic strategy to improve the OS of EOC patients. Our drug-hub gene interaction result was consistent with that of Katherine M Aird et al. Type 2 topoisomerase alpha (TOP2A) is a gene close to the HER2 gene that encodes a nuclear enzyme that is crucial in the cell cycle. Mano et al. first explored TOP2A amplifications in EOC [46], whereas in our study, we found that the type of alteration for TOP2A in SOC mainly included truncating mutations, missense mutations, and deep deletions (Fig. 5b). Mitotic checkpoint serine/threonine kinase B (BUB1B), the mammalian homolog of yeast Mad 3, is susceptible to cancer and causes chromosome loss and apoptotic cell death in human cancer cells [47, 48]. Many studies have reported that BUB1B is highly associated with advanced stages, serous histology and high grades in EOC, and a weakened spindle checkpoint with the downregulated expression of BUB1B is also related to acquired paclitaxel resistance in OC cells [49, 50]. Forhead box protein M1 (FOXM1), a transcription factor with a “winged helix” DNA-binding domain, plays a significant role in tumor progression through cell proliferation, tumor invasion, migration, and angiogenesis [51, 52]. Yu Wang et al. reported that FOXM1 promotes the reprogramming of glucose metabolism in EOC by activating GLUT1 and HK2 transcription [53]. Finally, baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) is an inhibitor of apoptosis that is always absent in normal tissues and is associated with various cancers, such as breast cancer and OC [54, 55]. Epithelial to mesenchymal transition (EMT) is a biological process that is associated with tumor metastasis and chemoresistance in ovarian tumors [56]. Zhao G et al. reported that higher expression of BIRC5 always promoted EMT in ovarian cancer cells [57]. In this study, both the cBioPortal and DGIldb databases considered BIRC5 to be a target of chemotherapy drugs used to treat OC (Fig. 5a, Table 3).

Furthermore, 10 genes were identified as the hub genes, and their expression levels in OC patients of different stages were all verified according to both the GEO and GEPIA2 databases. A list of 62 drugs with potential therapeutic efficacy against OC were selected (Table 3). For the 10 hub genes, the potential gene targets of these drugs were TYMS and BIRC5. However, the mechanisms of most of these drugs were unknown. The effects of the screened drugs were verified for many other types of cancers such as lung cancer, liver cancer, and colon cancer. Only a few of the TYMS- and BIRC5-targeting drugs have been used for OC treatment, such as fluorouracil/oxaliplatin (5-fluorouracil can induce the upregulation of human TYMS expression through TYMS mRNA transcription) [58], paclitaxel (the inhibition of BIRC5 expression can activate cell responses to paclitaxel treatment) [57], and carboplatin [59]. Additional studies and clinical trials are needed to identify and explore the drugs that are effective for OC treatment in future. Nevertheless, this study used multiple available databases to provide novel insights into the OC pathogenesis and treatment, and the identified conventional drugs might find potential new uses.
Therefore, considering the crucial roles of these 10 hub genes on the basis of this study and other previous studies mentioned above, further studies may be focused on exploring their precise mechanisms in the tumorigenesis and prognosis of OC, especially studying KIF4A, CCNB2, and CDC20. There were still several limitations in this study. One is that the microarray data and other analyses were obtained from many public databases, not generated by authors. The other is that only the TCGA and GEPIA2 databases were used to verify the expression levels of the hub genes, and experiments were not performed by the authors. Furthermore, due to a lack of experimental studies and verifications, we could not further explore how hub gene-miRNAs networks have effects on the diagnosis and therapy of ovarian cancer in depth. Despite these limitations, this study may provide more accurate results based on integrated bioinformatic analysis compared to the single dataset studies.

**Conclusions**

In summary, a total of 171 DEGs, including 114 upregulated DEGs and 57 downregulated DEGs in OC, were screened through integrated bioinformatic analysis, and 10 hub genes, namely, KIF4A, CDC20, CCNB2, TOP2A, RRM2, TYMS, KIF11, BIRC5, BUB1B, and FOXM1, may play crucial roles in the tumorigenesis and prognosis of OC. Among these hub genes, one gene, KIF4A, has not been previously reported to be related to OC, which indicates that KIF4A might be a potential biomarker for OC diagnosis and prognosis at an early stage. Additionally, the miRNA-hub gene network and potential targeted drugs related to these hub genes were constructed and selected, respectively, and may contribute to studying the mechanisms of OC. In-depth molecular mechanisms of the novel hub genes in OC are needed in future, and relevant experimental models can be constructed on the basis of these genes for the early detection, prognostic judgment, risk assessment, and targeted therapy of OC.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13048-020-0613-2.

**Additional file 1:** Heatmap of the differentially expressed genes (DEGs) between OC tissue and normal tissues.

**Additional file 2:** GO analysis of the downregulated DEGs.

**Additional file 3:** Upregulated genes identified in each category for the functional enrichment analysis.

**Additional file 4:** PPI network of 168 DEGs.

**Additional file 5:** Interaction network between the DEGs and their related genes.

**Additional file 6:** The four significant modules selected from the PPI network.

**Additional file 7:** KEGG pathway analysis of each module.

**Additional file 8:** Top 10 hub genes in the PPI network ranked by the degree method.

**Additional file 9:** Progression free survival analyses of the hub genes in early stage (stages 1 and 2) SOC patients.

**Additional file 10:** Progression free survival analyses of the hub genes in all stage OC patients.

**Additional file 11:** Progression free survival analyses of the hub genes in all stage SOC patients.

**Additional file 12:** Progression free survival analyses of the hub genes in advanced stage (stages 3 and 4) OC patients.

**Additional file 13:** Progression free survival analyses of the hub genes in advanced stage (stages 3 and 4) SOC patients.

**Additional file 14:** The respective miRNAs targeting the 10 hub genes.

**Additional file 15:** Targetable TYMS and BIRC5 subnetwork.

**Abbreviations**

BP: Biological process; CC: Cellular component; DAVID: Database for Annotation, Visualization and Integrated Discovery; DEGs: Differentially expressed genes; DGIdb: Drug-Gene Interaction Database; ENCORI: The Encyclopedia of RNA Interactomes; FDA: Food and Drug Administration; GEO: Gene Expression Omnibus; GEPIA2: Gene Expression Profiling Interactive Analysis; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; MCODE: Molecular Complex Detection; MF: Molecular function; OC: Ovarian cancer; PFS: Progression free survival; PPI: Protein-protein interaction; SOC: Serous ovarian cancer; STRING: Search Tool for the Retrieval of Interacting Genes/Proteins; TCGA: The Cancer Genome Atlas

**Acknowledgments**

We thank the GEO, TCGA, DAVID, KEGG, STRING, GEPIA2, STITCH, Kaplan-Meier plotter, and DGIdb databases for providing their platforms and the contributors for their valuable data sets.

**Authors’ contributions**

DY, YH, and BW collected and analyzed the data. YL designed and supervised the study. DY, YH, and YD drafted the first version of the manuscript. DY, YH, and YL reviewed and revised the manuscript. DY, ML and NW constructed the diagrams and tables of the article. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Environmental Health, School of Public Health, China Medical University, 77th Puhe Road, Shenyang 110122, Liaoning, China.

2 Department of Central Laboratory, The First Affiliated Hospital, China Medical University, 155th Nanjing North Street, Shenyang 110001, Liaoning, China.

3 Department of Anus and Intestine Surgery, The First Affiliated Hospital, China Medical University, 155th Nanjing North Street, Shenyang 110001, Liaoning, China.
Received: 16 September 2019 Accepted: 20 January 2020
Published online: 27 January 2020

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67(1):2–30.
2. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomark Prev. 2017;26(4):444–57.
3. Marie C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A, Rosen B, Engholm G, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol. 2012;127(1):75–82.
4. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, Bannon F, Ahn JV, Johnson C, Bonaventure A, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385(9972):977–1010.
5. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.
6. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.
7. Feng H, Gu ZY, Li Q, Liu QH, Yang XY, Zhang JJ. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 2019;12(1):35.
8. Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J, Zhao M. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol. 2016;33(11):130.
9. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–5.
10. Metsali T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heat map. Nucleic Acids Res. 2015;43(W1):W560–6.
11. Yang W, Zhao X, Han Y, Duan L, Lu X, Wang X, et al. Identification of hub genes and therapeutic drugs in esophageal squamous cell carcinoma based on integrated bioinformatics strategy. Cancer Cell Int. 2019;19:142.
12. Zheng MJ, Li X, Hu YX, Dong H, Gou R, Nie X, Liu Q, Ying-Ying H, Liu JJ, Lin B. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatical analysis and experiments. J Cell Physiol. 2019;234(7):11023–36.
13. Wang J, Shi F, Xu Z, Zhao M. Knockdown of elf4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells. Int J Oncol. 2015;47(6):2217–25.
14. Altman R. Current Progress in bioinformatics. 2016. Brief Bioinform. 2016;17(1):1.
15. Thuvajit C, Ferrarei A, Titone R, Thuvajit P, Itridoo C. The metabolic crosstalk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: autophagy plays a role. Med Res Rev. 2018;38(4):1235–54.
16. Craig ER, Londoño AI, Norian LA, Arend RC. Metabolic risk factors and progression: autophagy plays a role. Med Res Rev. 2018;38(4):1235–54.
17. Xia B, Yang S, Liu T, Lou G. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer. 2015;14:457.
18. Pourgholami MH, Mekkawy AH, Badar S, Morris DL. Minocycline inhibits doxorubicin-induced apoptosis in breast cancer cells. Mol Cells. 2014;37(11):812–8.
19. Hao G, Chen X, Cai Q, Shang Z, Niu Y. Increased KIF4A expression is a potential prognostic factor in prostate cancer. Onco Lett. 2018;15(3):9741–7.
20. Hou PF, Jiang T, Chen F, Shi PC, Li HQ, Bai J, Song J. KIF4A facilitates cell proliferation via induction of p21-mediated cell cycle progression and promotes metastasis in colorectal cancer. Cell Death Dis. 2018;9(5):477.
21. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishiuma T, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007;13(22 Pt 1):6624–31.
22. Wang A, Yoshimi N, Ino N, et al. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol. 1997;123(2):124–7.
23. Brandeis M, Rosewell I, Carrington M, et al. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci U S A. 1998;95(5):3444–9.
24. Gui L, Homer H. Hecl-dependent cyclin B2 stabilization regulates the G2-M transition and early prometaphase in mouse oocytes. Dev Cell. 2013;25(1):43–54.
25. Sun Y, Xiaoyan H, Yun L, Chaoqun L, Jialing W, Liu Y, Yingzi Z, Peipei Y, Junjun P, Yuanming L. Identification of key candidate genes and pathways for relationship between ovarian cancer and diabetes mellitus using bioinformatical analysis. Asian Pac J Cancer Prev. 2019;20(11):145–55.
26. Sun Q, Zhao H, Zhang C, et al. Gene co-expression network reveals shared modules predictive of stage and grade in serious ovarian cancers. Oncotarget. 2017;8(26):42983–96.
27. Kim Y, Choi JW, Lee JH, Kim YS. MADM2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol. 2014;33(5):157–23.
28. Moura IM, Delgado ML, Silva PM, Lopes CA, do Amaral JB, Monteiro LS, Boutsbaa H. High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2014;43(3):225–31.
29. Wu WJ, Hu KS, Wang DS, et al. CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med. 2013;11:442.
30. Bason P, Visentin M, Talimani R, et al. Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy. Pharmacogenomics. 2012;13(14):1609–19.
31. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM. Australian Cancer Study G, Kobel M, Anton-Culver H, Beedle J, Berchuck A, et al. Genetic variation in TVMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Eur J Epidemiol. 2009;24(7):1822–30.
32. Kelemen LE, Earp M, Fridey BL, Chenvev-Trench G, Australian Ovarian Cancer Study G, Fashing PA, Beckmann MW, Ekic AB, Hein A, Lambrechts D, et al. rs495139 in the TMY-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. Int J Mol Sci. 2018;19(9):2473.
33. Shi B, Bao J, Liu Y, Shi J. Death receptor 6 promotes ovarian cancer cell migration through KIF11. FEBS Open Bio. 2018;8(9):1497–507.
34. Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, et al. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond). 2013;124(5):567–78.
35. Jones DT, Lechertier T, Mitter R, Herbert JM, Bicknell R, Jones JL, Li JL, Buffa DL, et al. rs495139 in the TMY-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. Int J Mol Sci. 2018;19(9):2473.
36. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, et al. Gene expression level as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12(10):807–17.
37. Lin ZP, Belcourt MF, Cory JG, Sartorelli AC. Stable suppression of the R2 variant of ribonucleotide reductase by R2-targeted short interfering RNA sensitizes p53(−/−) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem. 2004;279(26):27030–8.
45. Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle. 2014;13(2):199–207.

46. Mano MS, Awada A, Di Leo A, Dubrecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol. 2004;92(3):887–95.

47. Kops GJ, Foltz DR, Cleveland DW, et al. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A. 2004;101(23):8699–704.

48. Wang Q, Liu T, Fang Y, Xie S, Huang X, Mahmood R, Ramaswamy G, Sakamoto KM, Darzynkiewicz Z, Xu M, et al. BUBR1 deficiency results in abnormal megalakaryopoiesis. Blood. 2004;103(4):1278–85.

49. Lee YK, Choi E, Kim MA, Park PG, Park NH, Lee H. SubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 2009;101(3):504–10.

50. Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV-3TR80. Gynecol Oncol. 2007;105(1):66–73.

51. Koo CY, Muir KW, Lam EW. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819(1):28–37.

52. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumour-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419.

53. Wang Y, Yun Y, Wu B, et al. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget. 2016;7(30):47985–97.

54. Ghaffari K, Hashemi M, Ebrahimi E, et al. BIRC3 genomic copy number variation in early-onset breast cancer. Iran Biomed J. 2016;20(4):241–5.

55. Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, Sims M, Li W, Pfeffer LM, Guo Y, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFbeta pathway. Exp Clin Cancer Res. 2018;37(1):235.

56. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59–66.

57. Zhao GWQ, Gu Q, Qian W, Wei JJ, Dong P, Watari H, Li W, Yue J. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget. 2017;8(55):94666–80.

58. Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fluouracil induced up-regulation of human thymidylate synthase expression. PLoS One. 2012;7(10):e47318.

59. Dziegielewksa B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK. T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer Ther. 2016;15(3):460–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.